It has been documented that, postmenopausal women with hormone-receptor positive (HR+), human epidermal growth factor receptor type2-negative (HER2-) tumors represent the majority of advanced breast cancer patients[4, 5]. This evidence concerns the gene NR4A1 and breast cancer.